Publications by authors named "Brian D Harms"

Claim this Profile
M
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.
Jessica B Casaletto, Melissa L Geddie, Adnan O Abu-Yousif, Kristina Masson, Aaron Fulgham, Brian D Harms

Proc Natl Acad Sci U S A· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons learned from quantitative dynamical modeling in systems biology.
Andreas Raue, Marcel Schilling, Julie Bachmann, Andrew Matteson, Max Schelker, Brian D Harms

PLoS One· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.
Jonathan B Fitzgerald, Bryan W Johnson, Jason Baum, Sharlene Adams, Sergio Iadevaia, Brian D Harms

Mol Cancer Ther· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies.
Brian D Harms, Jeffrey D Kearns, Sergio Iadevaia, Alexey A Lugovskoy

Methods· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.
Yu Zhou, Anne-Laure Goenaga, Brian D Harms, Hao Zou, Jianlong Lou

Mol Cancer Ther· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
Brian D Harms, Jeffrey D Kearns, Stephen V Su, Neeraj Kohli, Ulrik B Nielsen

Methods Enzymol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
Charlotte F McDonagh, Alexandra Huhalov, Brian D Harms, Sharlene Adams, Violette Paragas

Mol Cancer Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systems biologists seek fuller integration of systems biology approaches in new cancer research programs.
Olaf Wolkenhauer, Charles Auffray, Simone Baltrusch, Nils Blüthgen, Helen Byrne, Brian D Harms

Cancer Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.
Birgit Schoeberl, Emily A Pace, Jonathan B Fitzgerald, Brian D Harms, Lihui Xu

Sci Signal· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Directional persistence of EGF-induced cell migration is associated with stabilization of lamellipodial protrusions.
Brian D Harms, Gina M Bassi, Alan Rick Horwitz, Douglas A Lauffenburger

Biophys J· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis